6533b7dbfe1ef96bd12715b9
RESEARCH PRODUCT
Lack of association of the -463 G/A myeloperoxidase promoter polymorphism with Behcet's disease in Italian patients.
E. FarnettiI. OlivieriCarlo SalvaraniPiercarlo Sarzi-puttiniB. CasaliG. PaolazziF. CantiniF. SalviFabiola AtzeniN. PipitoneR La CorteL BoiardiD. FilippiniGiovanni Triolosubject
AdultMalemedicine.medical_specialtySystemic diseaseAdult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism GeneticHeterozygoteGenotypeBehcet's diseaseBehçet's disease; Disease manifestation; Myeloperoxidase; Myeloperoxidase gene polymorphism; Adult; Behcet Syndrome; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Histocompatibility Testing; Humans; Male; Peroxidase; Promoter Regions Genetic; Polymorphism Genetic; Rheumatology; Pharmacology (medical)Promoter RegionsRheumatologyGeneticGene FrequencyInternal medicineGenotypemedicineHumansPharmacology (medical)Genetic Predisposition to DiseaseAllelePolymorphismPromoter Regions GeneticPeroxidasePolymorphism Geneticbiologybusiness.industryBehcet SyndromeHistocompatibility TestingOdds ratiomedicine.diseaseRheumatologyGenotype frequencyMyeloperoxidaseImmunologybiology.proteinFemalebusinessdescription
Objective. To investigate potential associations between the � 463G/A myeloperoxidase (MPO) promoter polymorphism and susceptibility to, and clinical expression of, Behcet's disease (BD). Methods. One hundred and seventy-five Italian patients who satisfied the International Study Group criteria for BD and 235 healthy age- and sex-matched blood donors were genotyped for the �463G/A promoter polymorphism of the MPO gene by molecular methods. The patients were subgrouped according to the presence or absence of clinical manifestations. Results. The distribution of allele and genotype frequencies of the MPO �463A/G polymorphism did not differ significantly between the BD patients and the healthy controls. Carriers of the �463A allele (A/A or A/G) (odds ratio (OR) 0.7, 95% confidence interval (CI) 0.5-1.1) and homozygosity for A allele (OR 0.3, 95% CI 0.1-1.3) were less frequent among BD patients than among the controls, but the difference was not statistically significant. No significant associations were found when BD patients with and those without clinical manifestations were compared. Conclusion. Our data suggest that the �463G/A promoter polymorphism of the MPO gene is not associated with susceptibility to, and clinical expression of, BD in Italian patients.
year | journal | country | edition | language |
---|---|---|---|---|
2007-01-01 | Rheumatology (Oxford, England) |